Triomics Secures $22M for Cancer Data AI

Triomics, an AI company focused on oncology data, has secured $22 million in Series B funding. The round was led by Battery Ventures, with participation from existing investors Nexus Venture Partners, Lightspeed, and Y Combinator, along with strategic backers Oncology Ventures and Precision Health Informatics. This brings the company's total funding to over $36 million.

AI Tackles Oncology's Information Overload

The capital infusion will be used to expand Triomics' AI platform across cancer centers and life sciences organizations. The company's technology aims to operationalize complex clinical information, a significant challenge in cancer care.

Triomics is already working with major institutions including Memorial Sloan Kettering Cancer Center, MD Anderson, Yale Cancer Center, and Texas Oncology.

"Oncology faces an information burden at a scale legacy systems were never designed to handle," said Sarim Khan, co-founder and CEO of Triomics. "We built Triomics to turn that complexity into usable intelligence inside the workflow, purpose-built for oncology."

The platform uses AI agents to process longitudinal patient records, converting unstructured data into structured, verifiable insights delivered directly into clinical workflows. This approach supports proactive clinical trial matching, pre-visit chart review, and data abstraction for research and operations.

Published results indicate a 40% increase in trial matches and over 30% in enrollments, alongside a 67% reduction in chart review times for users of the Triomics product. The company's oncology AI platform has also received peer-review validation in Nature Digital Medicine.

Deepening Clinical Trial and Research Integration

Beyond provider workflows, Triomics is building a broader network to assist life sciences organizations with clinical trial operations. The company's oncology AI platform is designed to create a foundation for next-generation care and research applications.

"Getting a model to reason reliably across thousands of pages of notes, pathology, imaging and evolving trial criteria, and show its work, is what separates a demo from software that clinicians actually use," stated Hrituraj Singh, co-founder and CTO of Triomics.

The company highlights its ability to provide source-backed, verifiable outputs, differentiating it from simpler summarization tools. Its platform supports applications such as proactive clinical trial matching AI.

"Triomics built what oncology has always needed: AI infrastructure that actually works on the full patient record," said Brandon Gleklen, principal at Battery Ventures, who is joining the Triomics board.